⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SANG News
Sangoma Technologies Corporation Common Shares
Gene Editing Market to Reach US$30.5 Billion by 2033 as Precision Medicine and CRISPR Innovation Accelerate Growth - Persistence Market Research
prnewswire.com
CRSP
NTLA
TMO
SANG
Gene Editing Therapeutics: Transforming Biopharmaceuticals with 12.5% CAGR Growth Forecast
globenewswire.com
CRSP
NTLA
EDIT
BEAM
SANG
CELC
CRBU
PRME
Treg Cell-Based Therapies Clinical Trial Pipeline Appears Robust With 29+ Key Pharma Companies Actively Working in the Domain | DelveInsight
globenewswire.com
RAPT
SANG
INCY
ABBV
ARCT
AMGN
CHKP
PFE
LLY
SCLX
SNY
UCB
BIIB
NVS
VTRS
BMY
ABSI
ALEC
GSK
IONS
CLNN
ANNX
MED
GAM
VRTX
EXC
BLRX
Sangoma Announces CFO Transition: Larry Stock to Retire June 30; Adrian Back Named Interim CFO; Board Commences Search for Permanent Successor
businesswire.com
SANG
Carrier-Grade VoIP Platforms and Session Border Controller Infrastructure Research Report 2026: A $413.36 Billion Market by 2032 Featuring Nokia, Alianza, NetSapiens, Telnyx, 46 Labs, Sangoma, Ooma
globenewswire.com
NOK
SANG
OOMA
Sangoma Announces Third Quarter Fiscal 2026 Results
businesswire.com
SANG
Global DNA Microarray Market is Predicted to Exhibit Remarkable Growth at a CAGR of ~7% by 2034 | DelveInsight
globenewswire.com
CRSP
TMO
EDIT
LGL
SANG
PRGS
CELC
REGN
ILMN
MYGN
BIIB
DHR
ROST
QGEN
DGX
ABT
MRK
PACB
AZTA
Hemophilia Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
globenewswire.com
NVO
PFE
CSL
SNY
BMRN
ALNY
SANG
BE
REGN
NTLA
JNJ
ABBV
BMY
TEO
VRTX
CRSP
Sangoma Announces Date of Third Quarter Fiscal 2026 Financial Results and Conference Call
businesswire.com
SANG
Sangoma Renews Normal Course Issuer Bid
businesswire.com
SANG